Utilizing our Immune Therapy Platform Technology we intend to develop pipeline Product candidates. These discovery stage Product candidates are addressing other pathogen-related, allergic or malignant diseases.
Allergic diseases are caused by a pathogenic Th2-type immune response induced by different allergens. We believe that our DermAll Products will suppress pathogenic immune responses in allergic people by boosting allergen-specific Th1-type immune responses. This new mechanism is expected to restore a balanced Th1/Th2 immune response that is normally characteristic for people who do not have any allergic disease. The DermAll Product Portfolio will target several different allergies. The first target will be House Dust Mite (HDM), since we have already collected preclinical animal data in this DermAll indication suggesting that DermAll-HDM treatment can suppress allergic sneezing by balancing Th1/Th2 immunity.
For allergic diseases Immune Therapy offers a vastly different treatment option with disease-modifying potential to traditional symptomatic treatments. The major limitations of present Immune Therapy approaches include serious safety concerns and cost of treatment, therefore conventional symptomatic treatments continue to be the more popular option (Datamonitor 2010). DermAll Immune Therapy addresses both limitations using our proprietary API design to obtain Products with clinically proven excellent safety features, and cost effective manufacturing technology.